Johns Hopkins Team Develops Therapeutic, Nasally-Delivered DNA Vaccine for Tuberculosis
This image was generated by AI and may not depict real events.
Researchers at Johns Hopkins Medicine have developed a nasally-delivered DNA vaccine for tuberculosis, which shows promise in fighting the disease. The vaccine, which combines two genes, has been shown to help infected mice clear the disease bacteria faster and reduce lung inflammation.
A team at Johns Hopkins Medicine is developing a nose-delivered vaccine against tuberculosis. The vaccine combines two genes, relMtb and Mip3α, to direct the immune system to fight drug-tolerant bacteria. In mouse studies, the vaccine improved immune responses and reduced bacterial counts. The vaccine was also tested on primates, with promising results. The World Health Organization estimates that 2 billion people spread tuberculosis asymptomatically. The new vaccine could help meet the need for therapeutic vaccines to shorten treatment regimens and improve outcomes.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.